Abbott Laboratories (ABT)
NYSE: ABT
· Real-Time Price · USD
131.34
2.06 (1.59%)
At close: Aug 15, 2025, 10:14 AM
Abbott Laboratories Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 11.14B | 10.36B | 10.97B | 10.63B | 10.38B | 9.96B | 10.24B | 10.14B | 9.98B | 9.75B | 10.09B | 10.41B | 11.26B | 11.89B | 11.47B | 10.93B | 10.22B | 10.46B |
Cost of Revenue | 4.8B | 4.91B | 5.38B | 5.21B | 5.07B | 4.94B | 4.98B | 5.11B | 5.03B | 4.94B | 5.12B | 5.2B | 5.48B | 5.53B | 5.26B | 4.87B | 4.85B | 4.89B |
Gross Profit | 6.34B | 5.44B | 5.6B | 5.43B | 5.3B | 5.02B | 5.26B | 5.03B | 4.95B | 4.8B | 4.97B | 5.21B | 5.77B | 6.37B | 6.21B | 6.06B | 5.38B | 5.57B |
Operating Income | 2.1B | 1.69B | 1.99B | 1.82B | 1.69B | 1.39B | 1.86B | 1.68B | 1.51B | 1.4B | 1.44B | 1.7B | 2.33B | 2.88B | 2.45B | 2.62B | 2B | 2.13B |
Interest Income | n/a | 82M | 91M | 91M | 82M | 80M | 89M | 97M | 98M | 101M | 88M | 55M | 26M | 14M | 11M | 10M | 11M | 11M |
Pretax Income | 2.15B | 1.78B | 2.03B | 1.94B | 1.61B | 1.44B | 1.79B | 1.67B | 1.64B | 1.56B | 1.32B | 1.76B | 2.35B | 2.88B | 2.33B | 2.49B | 1.35B | 2.04B |
Net Income | 1.78B | 1.32B | 9.23B | 1.65B | 1.3B | 1.23B | 1.59B | 1.44B | 1.38B | 1.32B | 1.03B | 1.44B | 2.02B | 2.45B | 1.99B | 2.1B | 1.19B | 1.79B |
Selling & General & Admin | 3.09B | 3.05B | 2.88B | 2.9B | 2.92B | 2.95B | 2.7B | 2.69B | 2.72B | 2.75B | 2.84B | 2.73B | 2.76B | 2.79B | 3B | 2.77B | 2.72B | 2.78B |
Research & Development | 732M | 703M | 728M | 713M | 697M | 683M | 690M | 661M | 710M | 654M | 691M | 780M | 684M | 697M | 758M | 672M | 654M | 654M |
Other Expenses | 420M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.25B | 3.76B | 3.61B | 3.61B | 3.62B | 3.64B | 3.39B | 3.36B | 3.43B | 3.4B | 3.53B | 3.51B | 3.44B | 3.48B | 3.76B | 3.44B | 3.38B | 3.44B |
Interest Expense | 50M | 134M | 152M | 166M | 168M | 117M | 235M | 148M | 153M | 162M | 164M | 56M | 85M | 10M | 89M | 119M | 136M | 66M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.04B | 8.67B | 8.98B | 8.82B | 8.69B | 8.58B | 8.38B | 8.46B | 8.47B | 8.35B | 8.65B | 8.71B | 8.92B | 9.01B | 9.02B | 8.31B | 8.22B | 8.32B |
Income Tax Expense | 371M | 453M | -7.2B | 294M | 305M | 211M | 201M | 235M | 261M | 244M | 287M | 323M | 334M | 429M | 338M | 393M | 159M | 250M |
Shares Outstanding (Basic) | 1.74B | 1.75B | 1.73B | 1.73B | 1.73B | 1.73B | 1.73B | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | 1.75B | 1.75B | 1.76B | 1.77B | 1.77B | 1.78B |
Shares Outstanding (Diluted) | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.76B | 1.76B | 1.77B | 1.78B | 1.79B | 1.79B | 1.79B |
EPS (Basic) | 1.02 | 0.76 | 5.33 | 0.95 | 0.75 | 0.71 | 0.92 | 0.83 | 0.79 | 0.76 | 0.59 | 0.82 | 1.15 | 1.40 | 1.13 | 1.19 | 0.67 | 1.01 |
EPS (Diluted) | 1.02 | 0.76 | 5.27 | 0.94 | 0.74 | 0.70 | 0.91 | 0.82 | 0.78 | 0.75 | 0.59 | 0.81 | 1.14 | 1.38 | 1.12 | 1.17 | 0.66 | 1.00 |
EBITDA | 2.2B | 2.67B | 2.99B | 2.91B | 2.58B | 2.36B | 2.84B | 2.64B | 2.59B | 2.53B | 2.29B | 2.63B | 3.26B | 3.71B | 3.3B | 3.46B | 2.36B | 3.04B |
EBIT | 2.2B | 1.91B | 2.18B | 2.11B | 1.77B | 1.55B | 2.03B | 1.82B | 1.79B | 1.72B | 1.48B | 1.81B | 2.44B | 2.89B | 2.42B | 2.61B | 1.48B | 2.11B |
Depreciation & Amortization | n/a | 756M | 807M | 801M | 805M | 805M | 813M | 824M | 800M | 806M | 807M | 815M | 822M | 823M | 883M | 847M | 874M | 934M |